Kenneth W Mahaffey, MD

Offices

4 locations · Stanford Health Care · 3,152 clinicians in this group

Looking this up.

Hospitals listed: Stanford Health Care. That is not proof they admit you there this week.

Plans that list them

17 plans · 3 carriers

A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Mahaffey’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.

17 of 17 plans

Sort by

Plans whose provider directory lists this clinician

Alignment Health BreathEasy (HMO C-SNP)	Alignment Health Plan	Listed	Oct 3, 2026
Alignment Health Clarity (HMO C-SNP)	Alignment Health Plan	Listed	Oct 3, 2026
Alignment Health Harmony (HMO)	Alignment Health Plan	Listed	Oct 3, 2026
Alignment Health Heart & Diabetes (HMO C-SNP)	Alignment Health Plan	Listed	Oct 3, 2026
Alignment Health Heart & Diabetes CalPlus (HMO C-SNP)	Alignment Health Plan	Listed	Oct 3, 2026
Alignment Health Heart & Diabetes Care (HMO C-SNP)	Alignment Health Plan	Listed	Sep 28, 2026
Alignment Health Heart & Diabetes Choice (HMO C-SNP)	Alignment Health Plan	Listed	Sep 28, 2026
Alignment Health Honor+ Plan (HMO)	Alignment Health Plan	Listed	Oct 3, 2026
Alignment Health My Choice CalCare (HMO)	Alignment Health Plan	Listed	Oct 3, 2026
Alignment Health Silicon (HMO C-SNP)	Alignment Health Plan	Listed	Oct 3, 2026
Alignment Health smartHMO (HMO)	Alignment Health Plan	Listed	Oct 3, 2026
Alignment Health the ONE (HMO)	Alignment Health Plan	Listed	Oct 3, 2026
SCAN Balance (HMO C-SNP)	SCAN Health Plan	Listed	Oct 3, 2026
SCAN Classic (HMO)	SCAN Health Plan	Listed	Oct 3, 2026
SCAN MyChoice (HMO)	SCAN Health Plan	Listed	Oct 3, 2026
SCAN Strive (HMO C-SNP)	SCAN Health Plan	Listed	Oct 3, 2026
DualConnect (HMO D-SNP)	Santa Clara Family Health Plan	Listed	Sep 1, 2026

California Medical Board record

Licence G129600 · Current

Licensed to practise in California · since 2014 · expires 2028-04-30 · University of Washington School of Medicine.

No disciplinary actions, convictions, malpractice judgments or citations in this record.

Hospitals they work in

1 hospital

These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.

Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend it
Overall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024

See every measure and the patient survey for Stanford Health Care

Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.

Sort by

Every scored measure at Stanford Health Care

Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths	5.31 (4.24 to 6.37) · 8,661 cases	Worse	Jul 2022 – Jun 2024
Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits	14.1 (12.7 to 15.7) · 2,191 cases	Worse	Jan 2024 – Dec 2024
Postoperative respiratory failure rateComplications and deaths	4.08 (1.95 to 6.21) · 5,296 cases	Better	Jul 2022 – Jun 2024
Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections	0.317	Better	Oct 2024 – Sep 2025
Clostridium Difficile (C.Diff)Infections	0.446	Better	Oct 2024 – Sep 2025
SSI - Colon SurgeryInfections	0.241	Better	Oct 2024 – Sep 2025
Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits	0.7 (0.6 to 0.9) · 3,348 cases	Better	Jan 2024 – Dec 2024
Abdominopelvic accidental puncture or laceration rateComplications and deaths	1.06 (0.45 to 1.67) · 5,374 cases	No different	Jul 2022 – Jun 2024
CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths	0.86 (0.72 to 1)	No different	Jul 2022 – Jun 2024
Death rate among surgical inpatients with serious treatable complicationsComplications and deaths	166.09 (137.88 to 194.3) · 470 cases	No different	Jul 2022 – Jun 2024
Death rate for CABG surgery patientsComplications and deaths	1.1 · 192 cases	None	Jul 2022 – Jun 2025
Death rate for COPD patientsComplications and deaths	6.4 · 146 cases	None	Jul 2022 – Jun 2025
Death rate for heart attack patientsComplications and deaths	9.7 · 253 cases	None	Jul 2022 – Jun 2025
Death rate for heart failure patientsComplications and deaths	6.3 · 880 cases	None	Jul 2022 – Jun 2025
Death rate for pneumonia patientsComplications and deaths	10.3 · 935 cases	None	Jul 2022 – Jun 2025
Death rate for stroke patientsComplications and deaths	8.7 · 501 cases	None	Jul 2023 – Jun 2025
Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths	2.1 · 7,730 cases	None	Jul 2024 – Jun 2025
Iatrogenic pneumothorax rateComplications and deaths	0.13 (0 to 0.27) · 20,799 cases	No different	Jul 2022 – Jun 2024
In-hospital fall-associated fracture rateComplications and deaths	0.28 (0.14 to 0.43) · 23,182 cases	No different	Jul 2022 – Jun 2024
Postoperative acute kidney injury requiring dialysis rateComplications and deaths	0.94 (0.2 to 1.68) · 5,694 cases	No different	Jul 2022 – Jun 2024
Postoperative hemorrhage or hematoma rateComplications and deaths	2.36 (1.54 to 3.19) · 7,846 cases	No different	Jul 2022 – Jun 2024
Postoperative sepsis rateComplications and deaths	5.2 (3.76 to 6.64) · 5,603 cases	No different	Jul 2022 – Jun 2024
Postoperative wound dehiscence rateComplications and deaths	1.38 (0.23 to 2.53) · 2,211 cases	No different	Jul 2022 – Jun 2024
Pressure ulcer rateComplications and deaths	0.52 (0.21 to 0.83) · 19,915 cases	No different	Jul 2022 – Jun 2024
Rate of complications for hip/knee replacement patientsComplications and deaths	3.6 · 416 cases	None	Apr 2023 – Mar 2025
Central Line Associated Bloodstream Infection (ICU + select Wards)Infections	0.869	No different	Oct 2024 – Sep 2025
MRSA BacteremiaInfections	0.857	No different	Oct 2024 – Sep 2025
SSI - Abdominal HysterectomyInfections	0.368	No different	Oct 2024 – Sep 2025
Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits	16.2 · 247 cases	None	Jul 2023 – Jun 2025
Heart failure (HF) 30-Day Readmission RateUnplanned return visits	20.5 · 1,021 cases	None	Jul 2023 – Jun 2025
Hospital return days for heart attack patientsUnplanned return visits	47.8 · 258 cases	None	Jul 2022 – Jun 2025
Hospital return days for heart failure patientsUnplanned return visits	-1.6 · 990 cases	None	Jul 2022 – Jun 2025
Hospital return days for pneumonia patientsUnplanned return visits	20.8 · 976 cases	None	Jul 2022 – Jun 2025
Pneumonia (PN) 30-Day Readmission RateUnplanned return visits	16.5 · 959 cases	None	Jul 2023 – Jun 2025
Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits	5.2 (4.4 to 6.2) · 2,191 cases	No different	Jan 2024 – Dec 2024
Rate of readmission after hip/knee replacementUnplanned return visits	5.1 · 425 cases	None	Jul 2023 – Jun 2025
Rate of readmission for CABGUnplanned return visits	9.6 · 158 cases	None	Jul 2023 – Jun 2025
Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits	19.6 · 183 cases	None	Jul 2023 – Jun 2025
Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits	12.7 (10.4 to 15.4) · 4,578 cases	No different	Jan 2022 – Dec 2024

What patients said (6,810 patients answered, 25% of those asked)

Sort by

Patient survey stars by topic at Stanford Health Care

Cleanliness	4
Nurse communication	4
Doctor communication	4
Communication about medicines	3
Discharge information	4
Overall hospital rating	4
Quietness	2
Recommend hospital	5

Sort by

Share of patients giving the best answer at Stanford Health Care

Room was "always" clean	75%
Nurses "always" communicated well	82%
Doctors "always" communicated well	81%
Staff "always" explained	63%
Yes, staff "did" give patients this information	89%
Yes, staff "did" give patients information about help after discharge	89%
Doctors "always" explained things so they could understand	76%
Doctors "always" listened carefully	80%
Doctors "always" treated them with courtesy and respect	87%
Patients who gave a rating of "9" or "10" (high)	79%
Staff "always" explained new medications	76%
Nurses "always" explained things so they could understand	77%
Nurses "always" listened carefully	79%
Nurses "always" treated them with courtesy and respect	88%
"Always" quiet at night	53%
"YES", patients would definitely recommend the hospital	83%
Staff "always" explained possible side effects	50%
Yes, staff "did" give patients information about possible symptoms	90%

Original Medicare doctor bills

$16,078

Medicare paid this office $16,078 for 845 people.

This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.

Sort by

Largest Original Medicare bills

Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only	672	$5,184	$7
Long return visit (40+ min)	28	$4,377	$151
Heart rhythm review and interpretation of continous external ekg over 8-15 days	65	$1,515	$23
Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes	19	$1,354	$71
Subsequent hospital care with moderate levelof medical decision making at least 35 minutes	15	$1,271	$71

See all 8 services

Sort by

Every Original Medicare service billed

Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only	672	$5,184	$7
Long return visit (40+ min)	28	$4,377	$151
Heart rhythm review and interpretation of continous external ekg over 8-15 days	65	$1,515	$23
Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes	19	$1,354	$71
Subsequent hospital care with moderate levelof medical decision making at least 35 minutes	15	$1,271	$71
Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes	15	$702	$44
Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report	20	$282	$14
Heart rhythm review, and interpretation of continous external ekg over more than 48 hours up to 7 days	11	$227	$21

Who their Medicare patients are

845 Original Medicare patients in 2024. Average age 75 · Under 65 10% · 85 and older 18% · Women 52% · Also on Medicaid 30% · Health risk score 2.36. Above the middle of the specialty; the typical cardiology clinician is at 1.71.

Conditions among them: High blood pressure 75% · Coronary heart disease 47% · Atrial fibrillation 45% · Heart failure 43% · Chronic kidney disease 43% · Diabetes 39% · Depression 27% · Cancer 23% · COPD 21% · Dementia 19% · Stroke 17%.

The office billed $108,360, Medicare allowed $21,613 and paid $16,078; for 966 services of 14 kinds.

Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.

Year by year

Sort by

Original Medicare by year

2024	845	966	75	2.36	$108,360	$16,078
2023	190	278	74	2.53	$76,614	$14,156
2022	480	637	74	2.29	$113,939	$20,459
2021	613	784	74	2.21	$108,199	$17,203
2020	319	423	73	2.77	$77,367	$13,785
2019	382	484	74	2.29	$71,697	$15,108
2018	161	262	74	2.57	$44,414	$12,486
2017	632	810	73	2.24	$73,830	$13,477
2016	90	151	76	2.02	$39,032	$10,131
2015	69	138	75	2.33	$34,503	$9,171
2014	51	65	75	1.72	$18,015	$4,000
2013	70	161	71	2.78	$35,329	$11,530

Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.

See the services billed each year

2023: 7 services

Sort by

Original Medicare services billed in 2023

Long return visit (40+ min)	22	$4,413	$163
Subsequent hospital care with moderate levelof medical decision making at least 35 minutes	18	$1,970	$73
Return visit (30+ min)	13	$1,597	$106
Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes	15	$1,058	$71
Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes	19	$994	$45
Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only	98	$763	$7
Heart rhythm review and interpretation of continous external ekg over 8-15 days	25	$575	$22

2022: 7 services

Sort by

Original Medicare services billed in 2022

Subsequent hospital care with moderate levelof medical decision making at least 50 minutes	29	$4,413	$94
Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only	353	$3,014	$7
Long return visit (40+ min)	12	$2,502	$156
Subsequent hospital care with moderate levelof medical decision making at least 35 minutes	31	$2,338	$60
Return visit (30+ min)	16	$2,004	$100
Heart rhythm review and interpretation of continous external ekg over 8-15 days	26	$598	$23
Telehealth originating site facility fee	18	$436	$21

2021: 7 services

Sort by

Original Medicare services billed in 2021

Long return visit (40+ min)	21	$4,723	$148
Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only	535	$4,678	$8
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes	14	$1,909	$95
Subsequent hospital care with moderate levelof medical decision making at least 35 minutes	24	$1,881	$65
Return visit (30+ min)	13	$1,487	$106
Heart rhythm review and interpretation of continous external ekg over 8-15 days	24	$585	$23
Telehealth originating site facility fee	13	$368	$20

2020: 5 services

Sort by

Original Medicare services billed in 2020

Subsequent hospital care with moderate levelof medical decision making at least 50 minutes	14	$2,044	$97
Subsequent hospital care with moderate levelof medical decision making at least 35 minutes	22	$1,999	$69
Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only	236	$1,875	$7
Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes	12	$1,274	$98
Review and interpretation of external ekg recording for more than 48 hours up to 21 days	21	$520	$25

2019: 6 services

Sort by

Original Medicare services billed in 2019

Subsequent hospital care with moderate levelof medical decision making at least 35 minutes	50	$5,017	$66
Return visit (30+ min)	21	$2,559	$78
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes	20	$2,453	$94
Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only	275	$2,213	$8
Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes	12	$1,090	$91
Review and interpretation of external ekg recording for more than 48 hours up to 21 days	25	$613	$24

2018: 4 services

Sort by

Original Medicare services billed in 2018

Subsequent hospital care with moderate levelof medical decision making at least 35 minutes	33	$4,053	$65
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes	19	$2,848	$92
Return visit (30+ min)	16	$2,301	$61
Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only	94	$767	$8

2017: 5 services

Sort by

Original Medicare services billed in 2017

Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only	545	$4,792	$7
Subsequent hospital care with moderate levelof medical decision making at least 35 minutes	25	$2,526	$65
Return visit (30+ min)	13	$1,160	$64
Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes	14	$873	$35
Review and interpretation of external ekg recording for more than 48 hours up to 21 days	27	$636	$24

2016: 4 services

Sort by

Original Medicare services billed in 2016

Subsequent hospital care with moderate levelof medical decision making at least 35 minutes	29	$3,086	$64
Hospital discharge day management, more than 30 minutes	12	$1,264	$97
Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes	11	$663	$35
Review and interpretation of external ekg recording for more than 48 hours up to 21 days	18	$433	$24

2015: 2 services

Sort by

Original Medicare services billed in 2015

Subsequent hospital care with moderate levelof medical decision making at least 35 minutes	19	$3,041	$65
Review and interpretation of external ekg recording for more than 48 hours up to 21 days	18	$435	$24

2014: 1 service

Sort by

Original Medicare services billed in 2014

Review and interpretation of external ekg recording for more than 48 hours up to 21 days	31	$752	$24

2013: 3 services

Sort by

Original Medicare services billed in 2013

Subsequent hospital care with moderate levelof medical decision making at least 50 minutes	56	$8,497	$77
Hospital discharge day management, more than 30 minutes	19	$1,596	$80
Hospital discharge day management, 30 minutes or less	13	$701	$54

Medicaid work

$5,133 in 2024

Medicaid paid $5,133 for 480 billed services this clinician did in 2024, up to 110 people in a month for one service.

Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.

Sort by

Largest Medicaid services in 2024

Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only	480	$5,133

Sort by

Medicaid work by year

2024	480	1	110	$5,133
2023	82	1	80	$848
2022	333	1	111	$3,740
2021	460	1	122	$5,292
2020	240	1	88	$2,895
2019	206	1	72	$2,401
2018	55	1	50	$636

See the largest Medicaid services in earlier years

2023

Sort by

Largest Medicaid services in 2023

Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only	82	$848

2022

Sort by

Largest Medicaid services in 2022

Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only	333	$3,740

2021

Sort by

Largest Medicaid services in 2021

Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only	460	$5,292

2020

Sort by

Largest Medicaid services in 2020

Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only	240	$2,895

2019

Sort by

Largest Medicaid services in 2019

Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only	206	$2,401

2018

Sort by

Largest Medicaid services in 2018

Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only	55	$636

Drugs they prescribed that Part D paid

$39,617

Pharmacies billed $39,617 in 2024.

This is pharmacy cost, not the office bill, and not what patients paid.

Opioids were 0% of their Part D prescriptions (0 of 233) in 2024. At or below the middle of the specialty; the typical cardiology clinician is at 0%.

189 generic and 44 brand-name prescriptions · $39,617 in drug cost.

Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.

Sort by

Largest Part D drug costs

Praluent	13	$6,044	$465
Ezetimibe	18	$809	$45
Metoprolol	21	$409	$19
Atorvastatin	29	$324	$11
Clopidogrel	14	$163	$12

See all 8 drugs

Sort by

Every Part D drug this clinician prescribed

Praluent	13	$6,044	$465
Ezetimibe	18	$809	$45
Metoprolol	21	$409	$19
Atorvastatin	29	$324	$11
Clopidogrel	14	$163	$12
Rosuvastatin	16	$103	$6
Losartan	31	$80	$3
Diltiazem 24hr Er	13	$49	$4

Year by year

Sort by

Part D prescribing by year

2024	233	29	0% (0)	19%	$39,617
2023	206	32	0% (0)	12%	$33,848
2022	245	30	0% (0)	17%	$41,866
2021	143	30	0% (0)	24%	$29,428
2020	76	26	0% (0)	None	$5,046
2019	127	17	0% (0)	19%	$8,852
2018	134	17	0% (0)	None	$5,044
2017	86	17	0% (0)	None	$2,904
2016	81	24	0% (0)	22%	$5,818
2015	39	13	0% (0)	None	$3,611
2014	25	None	0% (0)	None	$774
2013	135	19	0% (0)	16%	$4,985

Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.

See the drugs prescribed each year

2023: 7 drugs

Sort by

Part D drugs prescribed in 2023

Praluent	11	$5,781	$526
Ezetimibe	16	$952	$60
Atorvastatin	37	$706	$19
Losartan	26	$675	$26
Metoprolol	12	$595	$50
Clopidogrel	11	$260	$24
Rosuvastatin	17	$105	$6

2022: 7 drugs

Sort by

Part D drugs prescribed in 2022

Praluent	14	$7,031	$502
Atorvastatin	32	$626	$20
Losartan	21	$398	$19
Metoprolol	15	$330	$22
Clopidogrel	12	$193	$16
Metoprolol	13	$90	$7
Diltiazem 24hr Er (Cd)	11	$58	$5

2021: 3 drugs

Sort by

Part D drugs prescribed in 2021

Praluent	13	$6,236	$480
Metoprolol	18	$368	$20
Atorvastatin	19	$306	$16

2020: 1 drug

Sort by

Part D drugs prescribed in 2020

Metoprolol	11	$218	$20

2019: 5 drugs

Sort by

Part D drugs prescribed in 2019

Eliquis	11	$5,128	$466
Metoprolol	18	$550	$31
Isosorbide Mononitrate Er	12	$432	$36
Rosuvastatin	17	$336	$20
Atorvastatin	13	$220	$17

2018: 3 drugs

Sort by

Part D drugs prescribed in 2018

Metoprolol	25	$320	$13
Atorvastatin	15	$281	$19
Rosuvastatin	13	$230	$18

2017: 2 drugs

Sort by

Part D drugs prescribed in 2017

Metoprolol	26	$510	$20
Rosuvastatin	12	$479	$40

2016: 1 drug

Sort by

Part D drugs prescribed in 2016

Metoprolol	14	$233	$17

2015: 1 drug

Sort by

Part D drugs prescribed in 2015

Metoprolol	14	$314	$22

2013: 3 drugs

Sort by

Part D drugs prescribed in 2013

Pravastatin	16	$147	$9
Metoprolol	12	$44	$4
Lisinopril	11	$0	$0

Money from drug and device companies

$60,575 in 2025

Sort by

Industry payments by year

2025	5	25	$59,931	$60,575
2024	5	51	$45,695	$76,674
2023	4	43	$36,755	$40,369
2022	6	42	$112,987	$119,095
2021	2	11	$43,785	$43,922
2020	6	12	$30,048	$30,048
2019	13	54	$53,217	$75,853

Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.

A payment is not proof that care is biased.

Sort by

Payments by company

E.R. Squibb & Sons L.L.C.	None	$33,363	11 payments Consulting · 2025-11-26 · $650 Consulting · 2025-11-25 · $813 Consulting · 2025-09-30 · $5,200 Consulting · 2025-07-08 · $2,275 Consulting · 2025-07-07 · $2,275 Consulting · 2025-07-07 · $375 Consulting · 2025-06-26 · $5,200 Consulting · 2025-05-15 · $3,413 Consulting · 2025-05-14 · $3,413 Consulting · 2025-04-14 · $4,875 Consulting · 2025-04-11 · $4,875
Eli Lilly and	None	$18,400	4 payments Consulting · 2025-12-04 · $5,000 Consulting · 2025-09-26 · $3,600 Consulting · 2025-06-18 · $5,200 Consulting · 2025-01-03 · $4,600
ModernaTX	None	$5,000	4 payments Consulting · 2025-10-08 · $500 Consulting · 2025-10-08 · $2,750 Consulting · 2025-04-01 · $1,000 Consulting · 2025-01-08 · $750
CSL Behring	None	$3,168	1 payment Consulting · 2025-06-20 · $3,168
Janssen Research & Development	None	$644	5 payments Meals · 2025-08-28 · $55 Meals · 2025-03-29 · $40 Travel · 2025-03-28 · $389 Meals · 2025-03-28 · $100 Meals · 2025-03-28 · $60

See all 25 published payments

Sort by

Every published payment

Eli Lilly and	Consulting · 2025-12-04	None	$5,000
E.R. Squibb & Sons L.L.C.	Consulting · 2025-11-26	None	$650
E.R. Squibb & Sons L.L.C.	Consulting · 2025-11-25	None	$813
ModernaTX	Consulting · 2025-10-08	None	$500
ModernaTX	Consulting · 2025-10-08	None	$2,750
E.R. Squibb & Sons L.L.C.	Consulting · 2025-09-30	None	$5,200
Eli Lilly and	Consulting · 2025-09-26	None	$3,600
Janssen Research & Development	Meals · 2025-08-28	None	$55
E.R. Squibb & Sons L.L.C.	Consulting · 2025-07-08	None	$2,275
E.R. Squibb & Sons L.L.C.	Consulting · 2025-07-07	None	$2,275
E.R. Squibb & Sons L.L.C.	Consulting · 2025-07-07	None	$375
E.R. Squibb & Sons L.L.C.	Consulting · 2025-06-26	None	$5,200
CSL Behring	Consulting · 2025-06-20	None	$3,168
Eli Lilly and	Consulting · 2025-06-18	None	$5,200
E.R. Squibb & Sons L.L.C.	Consulting · 2025-05-15	None	$3,413
E.R. Squibb & Sons L.L.C.	Consulting · 2025-05-14	None	$3,413
E.R. Squibb & Sons L.L.C.	Consulting · 2025-04-14	None	$4,875
E.R. Squibb & Sons L.L.C.	Consulting · 2025-04-11	None	$4,875
ModernaTX	Consulting · 2025-04-01	None	$1,000
Janssen Research & Development	Meals · 2025-03-29	None	$40
Janssen Research & Development	Travel · 2025-03-28	None	$389
Janssen Research & Development	Meals · 2025-03-28	None	$100
Janssen Research & Development	Meals · 2025-03-28	None	$60
ModernaTX	Consulting · 2025-01-08	None	$750
Eli Lilly and	Consulting · 2025-01-03	None	$4,600

See earlier years (2024, 2023, 2022, 2021, 2020, 2019)

2024: $76,674

Sort by

Payments by company in 2024

E.R. Squibb & Sons L.L.C.	Camzyos	$32,995	10 payments Consulting for Camzyos · 2024-11-13 · $3,640 Consulting for Camzyos · 2024-11-07 · $4,550 Consulting for Camzyos · 2024-05-17 · $4,160 Consulting for Camzyos · 2024-05-07 · $2,300 Consulting for Camzyos · 2024-04-29 · $5,200 Consulting · 2024-02-01 · $1,820 Consulting · 2024-01-23 · $2,275 Consulting · 2024-01-19 · $1,900 Consulting · 2024-01-02 · $2,600 Consulting · 2024-01-02 · $4,550
Janssen Research & Development	Xarelto	$28,038	30 payments Meals · 2024-08-29 · $58 Meals · 2024-08-28 · $38 Travel · 2024-04-26 · $48 Meals · 2024-04-26 · $10 Travel · 2024-04-26 · $148 Travel · 2024-04-26 · $100 Travel · 2024-04-26 · $148 Meals · 2024-04-26 · $10 Meals · 2024-04-26 · $40 Meals · 2024-04-26 · $16 Meals · 2024-04-26 · $48 Travel · 2024-04-26 · $100 Travel · 2024-04-26 · $148 Meals · 2024-04-26 · $71 Travel · 2024-04-13 · $14,069 Meals for Xarelto · 2024-04-06 · $84 Meals · 2024-03-16 · $33 Meals · 2024-03-16 · $132 Meals · 2024-02-21 · $54 Meals · 2024-02-21 · $27 Travel · 2024-02-19 · $179 Meals · 2024-02-19 · $11 Travel · 2024-02-19 · $179 Travel · 2024-02-19 · $179 Travel · 2024-02-19 · $137 Meals · 2024-02-19 · $11 Meals · 2024-02-19 · $43 Meals · 2024-02-19 · $111 Meals · 2024-02-19 · $76 Travel · 2024-01-31 · $11,731
Eli Lilly and	None	$8,200	2 payments Consulting · 2024-09-30 · $3,800 Consulting · 2024-05-31 · $4,400
ModernaTX	None	$4,500	3 payments Consulting · 2024-10-09 · $1,250 Consulting · 2024-08-21 · $1,500 Consulting · 2024-02-07 · $1,750
Novo Nordisk AS	None	$2,941	6 payments Travel · 2024-08-30 · $473 Meals · 2024-08-30 · $43 Travel · 2024-06-24 · $858 Travel · 2024-06-24 · $1,093 Travel · 2024-06-24 · $300 Meals · 2024-06-24 · $173

2023: $40,369

Sort by

Payments by company in 2023

Janssen Research & Development	None	$19,079	22 payments Meals · 2023-11-10 · $20 Meals · 2023-11-09 · $90 Meals · 2023-10-05 · $57 Travel · 2023-09-13 · $157 Meals · 2023-09-13 · $150 Travel · 2023-09-13 · $249 Meals · 2023-09-13 · $40 Meals · 2023-09-13 · $20 Meals · 2023-09-13 · $60 Meals · 2023-09-13 · $20 Meals · 2023-09-12 · $53 Meals · 2023-08-24 · $15 Meals · 2023-08-24 · $39 Meals · 2023-08-24 · $15 Travel · 2023-08-09 · $553 Consulting · 2023-03-13 · $15,600 Meals · 2023-03-03 · $40 Meals · 2023-03-03 · $60 Meals · 2023-03-03 · $82 Meals · 2023-03-03 · $73 Meals · 2023-03-03 · $13 Travel · 2023-01-16 · $1,674
E.R. Squibb & Sons L.L.C.	Camzyos	$14,045	4 payments Consulting for Camzyos · 2023-12-12 · $8,938 Meals · 2023-10-31 · $135 Consulting for Camzyos · 2023-03-03 · $2,210 Consulting for Camzyos · 2023-02-15 · $2,763
ModernaTX	Moderna Covid-19 Vaccine	$4,000	16 payments Consulting for Moderna Covid-19 Vaccine · 2023-12-01 · $250 Consulting for Moderna Covid-19 Vaccine · 2023-12-01 · $250 Consulting for Moderna Covid-19 Vaccine · 2023-12-01 · $250 Consulting for Moderna Covid-19 Vaccine · 2023-12-01 · $250 Consulting for Moderna Covid-19 Vaccine · 2023-12-01 · $250 Consulting for Moderna Covid-19 Vaccine · 2023-12-01 · $250 Consulting · 2023-06-21 · $250 Consulting · 2023-06-21 · $250 Consulting · 2023-06-21 · $250 Consulting · 2023-06-21 · $250 Consulting for Moderna Covid-19 Vaccine · 2023-04-05 · $250 Consulting for Moderna Covid-19 Vaccine · 2023-04-05 · $250 Consulting for Moderna Covid-19 Vaccine · 2023-04-05 · $250 Consulting for Moderna Covid-19 Vaccine · 2023-04-05 · $250 Consulting for Moderna Covid-19 Vaccine · 2023-04-05 · $250 Consulting for Moderna Covid-19 Vaccine · 2023-04-05 · $250
Bayer Healthcare Pharmaceuticals	None	$3,245	1 payment Consulting · 2023-09-01 · $3,245

2022: $119,095

Sort by

Payments by company in 2022

Janssen Research & Development	None	$69,054	12 payments Consulting · 2022-11-25 · $31,200 Meals · 2022-11-07 · $43 Meals · 2022-11-05 · $48 Meals · 2022-11-03 · $23 Travel · 2022-08-25 · $64 Consulting · 2022-05-27 · $18,902 Travel · 2022-05-27 · $1,425 Meals · 2022-04-02 · $50 Meals · 2022-04-01 · $25 Meals · 2022-04-01 · $11 Meals · 2022-04-01 · $36 Consulting · 2022-03-14 · $17,225
CSL Behring	None	$23,622	8 payments Consulting · 2022-11-15 · $7,350 Paid to speak or teach · 2022-11-01 · $5,795 Consulting · 2022-10-19 · $2,700 Paid to speak or teach · 2022-06-16 · $6,558 Travel · 2022-06-16 · $420 Travel · 2022-06-16 · $593 Travel · 2022-06-16 · $106 Meals · 2022-06-16 · $101
Otsuka Pharmaceutical Development & Commercialization	None	$13,320	7 payments Consulting · 2022-08-12 · $1,680 Consulting · 2022-07-14 · $720 Consulting · 2022-06-14 · $2,760 Consulting · 2022-05-12 · $2,640 Consulting · 2022-04-13 · $1,320 Consulting · 2022-03-10 · $3,480 Consulting · 2022-01-10 · $720
Bayer HealthCare Pharmaceuticals	Kerendia	$11,975	13 payments Meals for Kerendia · 2022-10-28 · $9 Meals for Kerendia · 2022-10-28 · $11 Meals for Kerendia · 2022-10-28 · $15 Meals for Kerendia · 2022-10-28 · $13 Consulting for Kerendia · 2022-10-28 · $8,250 Travel for Kerendia · 2022-10-28 · $82 Travel for Kerendia · 2022-10-28 · $254 Travel for Kerendia · 2022-10-28 · $224 Travel for Kerendia · 2022-10-28 · $2,042 Meals for Kerendia · 2022-10-28 · $29 Travel for Kerendia · 2022-10-27 · $119 Travel for Kerendia · 2022-10-27 · $240 Consulting for Kerendia · 2022-02-02 · $688
ModernaTX	Moderna Covid-19 Vaccine	$1,000	1 payment Consulting for Moderna Covid-19 Vaccine · 2022-11-23 · $1,000
E.R. Squibb & Sons L.L.C.	None	$125	1 payment Meals · 2022-06-07 · $125

2021: $43,922

Sort by

Payments by company in 2021

Janssen Research & Development	None	$34,775	5 payments Consulting · 2021-11-26 · $3,250 Consulting · 2021-10-14 · $9,750 Consulting · 2021-08-13 · $10,400 Consulting · 2021-06-14 · $9,425 Consulting · 2021-04-07 · $1,950
Bayer HealthCare Pharmaceuticals	Kerendia	$9,147	6 payments Consulting for Kerendia · 2021-12-08 · $1,100 Consulting for Kerendia · 2021-11-11 · $3,098 Consulting for Kerendia · 2021-10-21 · $2,063 Meals for Kerendia · 2021-09-14 · $137 Consulting for Non-Covered · 2021-06-04 · $413 Consulting for Non-Covered · 2021-04-15 · $2,338

2020: $30,048

Sort by

Payments by company in 2020

Janssen Research & Development	None	$17,875	5 payments Consulting · 2020-11-23 · $3,900 Consulting · 2020-11-09 · $1,950 Consulting · 2020-06-22 · $2,600 Consulting · 2020-04-03 · $4,875 Consulting · 2020-02-17 · $4,550
Janssen Global Services	Invokana	$3,200	2 payments Consulting for Invokana · 2020-03-24 · $800 Consulting for Invokana · 2020-01-23 · $2,400
AstraZeneca Pharmaceuticals LP	Epanova	$3,000	1 payment Consulting for Epanova · 2020-01-10 · $3,000
Bayer HealthCare Pharmaceuticals	Non-Covered	$2,613	2 payments Consulting for Non-Covered · 2020-08-02 · $1,100 Consulting for Non-Covered · 2020-05-31 · $1,513
Janssen Scientific Affairs	Invokana	$1,800	1 payment Consulting for Invokana · 2020-09-18 · $1,800
CSL Behring	None	$1,560	1 payment Honoraria · 2020-12-23 · $1,560

2019: $75,853

Sort by

Payments by company in 2019

Janssen Research & Development	Invokana	$27,377	17 payments Travel · 2019-07-01 · $422 Consulting · 2019-07-01 · $7,475 Meals · 2019-07-01 · $100 Meals for Invokana · 2019-05-27 · $243 Travel for Invokana · 2019-05-27 · $418 Meals for Invokana · 2019-04-15 · $52 Meals for Invokana · 2019-04-11 · $74 Travel for Invokana · 2019-03-31 · $7,649 Meals · 2019-03-27 · $23 Meals · 2019-03-27 · $50 Meals for Invokana · 2019-02-28 · $160 Travel for Xarelto · 2019-02-22 · $318 Travel for Invokana · 2019-02-15 · $126 Meals for Invokana · 2019-02-15 · $99 Travel for Invokana · 2019-02-12 · $9,339 Travel for Invokana · 2019-01-31 · $441 Meals for Invokana · 2019-01-31 · $389
Novo Nordisk AS	None	$17,604	2 payments Travel · 2019-02-14 · $166 Consulting · 2019-02-14 · $17,438
AstraZeneca Pharmaceuticals LP	Epanova	$8,902	6 payments Consulting for Epanova · 2019-10-18 · $750 Consulting for Epanova · 2019-10-18 · $3,000 Travel for Epanova · 2019-04-04 · $133 Meals for Epanova · 2019-04-04 · $4 Consulting for Epanova · 2019-04-04 · $5,000 Travel for Epanova · 2019-04-04 · $16
Janssen Pharmaceuticals	Invokana	$6,072	3 payments Consulting for Invokana · 2019-11-26 · $1,575 Paid to speak or teach for Invokana · 2019-07-09 · $4,340 Travel for Invokana · 2019-07-09 · $157
Novartis Pharmaceuticals	Entresto	$5,020	3 payments Consulting · 2019-06-21 · $4,869 Travel · 2019-06-21 · $50 Meals for Entresto · 2019-02-08 · $101
CSL Behring	None	$4,186	6 payments Honoraria · 2019-11-15 · $3,510 Travel · 2019-11-15 · $410 Meals · 2019-11-15 · $96 Meals · 2019-11-15 · $8 Meals · 2019-11-15 · $29 Meals · 2019-04-23 · $133
Regeneron Pharmaceuticals	Praluent	$3,570	1 payment Consulting for Praluent · 2019-01-08 · $3,570
Sanofi US Services	Efpeglenatide	$1,690	3 payments Consulting for Efpeglenatide · 2019-12-31 · $845 Consulting for Efpeglenatide · 2019-12-31 · $195 Consulting for Efpeglenatide · 2019-11-30 · $650
AstraZeneca UK	Epanova	$1,058	7 payments Travel for Epanova · 2019-03-29 · $105 Travel for Epanova · 2019-03-29 · $274 Meals for Epanova · 2019-03-29 · $47 Meals for Epanova · 2019-03-29 · $16 Meals for Epanova · 2019-03-29 · $55 Travel for Epanova · 2019-03-28 · $402 Travel for Epanova · 2019-03-28 · $160
Janssen Scientific Affairs	Xarelto	$188	3 payments Meals for Xarelto · 2019-06-11 · $124 Meals for Xarelto · 2019-06-08 · $12 Meals for Invokana · 2019-04-15 · $52
Gilead Sciences	None	$98	1 payment Meals · 2019-11-06 · $98
Janssen Global Services	Invokana	$73	1 payment Meals for Invokana · 2019-02-06 · $73
Novo Nordisk	None	$14	1 payment Meals · 2019-02-14 · $14

Research money

Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.

Sort by

Research payments by company and study

Novo Nordisk Inc · Optimize the Treatment of Patients With Cardiovascular Disease · 2023	Their institution	$91,667
Janssen Research & Development, LLC · Protocol 28431754dne3001 A Randomized Double Blind Placebo Group Two Arm Multi Center Study To Assess the Efficacy of Canagliflozin on End Stage Kidney Disease and Vascular Death in Subjects With Type 2 Diabetes Mellitus and Nephropathy · 2019	Their institution	$91,611
Janssen Research & Development, LLC · Stanford University Rivaroxaban Trial 39039039chd3001; Phase 3 · 2020	Their institution	$64,804
Novo Nordisk AS · Ozempic · 2024	This clinician	$42,643
Quidel Corporation · Cs-0908-01-High Note · 2023	Their institution	$40,120
Janssen Research & Development, LLC · Protocol 28431754dne3001 A Randomized Double Blind Placebo Group Two Arm Multi Center Study To Assess the Efficacy of Canagliflozin on End Stage Kidney Disease and Vascular Death in Subjects With Type 2 Diabetes Mellitus and Nephropathy · 2020	Their institution	$36,225
Janssen Research & Development, LLC · Stanford University Rivaroxaban Trial 39039039chd3001; Phase 3 · 2019	Their institution	$32,465
Janssen Research & Development, LLC · A Prospective, Open-Label, Active-Controlled Study To Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Efficacy of Rivaroxaban for Thromboprophylaxis in Pediatric Subjects 2 To 8 Years of Age After the Fontan Procedure · 2021	Their institution	$31,712
Novo Nordisk AS · Ozempic · 2022	This clinician	$18,938
Otsuka Pharmaceutical Development & Commercialization, Inc. · Phase 3b, Randomized, Open-Label, Sponsor-Blind, Active-Controlled Study Evaluating the Efficacy and Safety of Oral Vadadustat, Once Daily (Qd) and Three Times Weekly (Tiw) for the Maintenance Treatment of Anemia in Hemodialysis Subjects Converting From Erythropoiesis-Stimulating Agents (Esas) · 2021	This clinician	$18,360
Janssen Research & Development, LLC · A Prospective, Open-Label, Active-Controlled Study To Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Efficacy of Rivaroxaban for Thromboprophylaxis in Pediatric Subjects 2 To 8 Years of Age After the Fontan Procedure · 2020	Their institution	$12,782
Novo Nordisk AS · Ozempic · 2023	This clinician	$10,269
Novo Nordisk AS · Ozempic · 2020	This clinician	$8,625
Novo Nordisk AS · 2021	This clinician	$8,250
SANOFI US SERVICES INC. · Efpeg Cvot · 2020	This clinician	$5,105
SANOFI US SERVICES INC. · A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study To Evaluate the Effect of Efpeglenatide on Cardiovascular Outcomes in Type 2 Diabetes Patients at High Cardiovascular · 2020	This clinician	$4,745
SANOFI US SERVICES INC. · A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study To Evaluate the Effect of Efpeglenatide on Cardiovascular Outcomes in Type 2 Diabetes Patients at High Cardiovascular Risk · 2020	This clinician	$4,335
Boehringer Ingelheim International GmbH · Conquest: Bi 1015550 in A Platform Trial in Ssc-Ild (Srf) · 2024	Their institution	$3,500
SANOFI US SERVICES INC. · A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study To Evaluate the Effect of Efpeglenatide on Cardiovascular Outcomes in Type 2 Diabetes Patients at High Cardiovascular Risk · 2021	This clinician	$2,365
SANOFI US SERVICES INC. · A 56-Week, Multicenter, Double-Blind, Placebo-Controlled, Randomized Study To Evaluate the Efficacy and Safety of Efpeglenatide Once Weekly in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Basal Insulin Alone Or in Combination With Oral Antidiabetic Drug(S) · 2021	This clinician	$195
SANOFI US SERVICES INC. · A 30-Week, Multicenter, Double-Blind, Placebo-Controlled, Randomized Study To Evaluate the Efficacy and Safety of Efpeglenatide Once Weekly in Patients With Type 2 Diabetes Mellitus Inadequately Contr · 2020	This clinician	$195
SANOFI US SERVICES INC. · Efpeg Non-Outcomes · 2020	This clinician	$130
SANOFI US SERVICES INC. · A 56-Week, Multicenter, Double-Blind, Placebo-Controlled, Randomized Study To Evaluate the Efficacy and Safety of Efpeglenatide Once Weekly in Patients With Type 2 Diabetes Mellitus Inadequately Contr · 2020	This clinician	$65
SANOFI US SERVICES INC. · A 30-Week, Multicenter, Double-Blind, Placebo-Controlled, Randomized Study To Evaluate the Efficacy and Safety of Efpeglenatide Once Weekly in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Alone Or in Combination With Sulfonylurea · 2021	This clinician	$65
SANOFI US SERVICES INC. · A 56-Week, Multicenter, Double-Blind, Placebo-Controlled, Randomized Study To Evaluate the Efficacy and Safety of Efpeglenatide Once Weekly in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Basal Insulin Alone Or in Combination With Oral Antidiabetic Drug(S) · 2020	This clinician	$65
SANOFI US SERVICES INC. · A 56-Week, Multicenter, Open-Label, Active-Controlled, Randomized Study To Evaluate the Efficacy and Safety of Efpeglenatide Once Weekly Compared To Dulaglutide Once Weekly in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin · 2020	This clinician	$65
SANOFI US SERVICES INC. · A 56-Week, Multicenter, Open-Label, Active-Controlled, Randomized Study To Evaluate the Efficacy and Safety of Efpeglenatide Once Weekly Compared To Dulaglutide Once Weekly in Patients With Type 2 Dia · 2020	This clinician	$65
SANOFI US SERVICES INC. · A 56-Week, Multicenter, Open-Label, Active-Controlled, Randomized Study To Evaluate the Efficacy and Safety of Efpeglenatide Once Weekly Compared To Dulaglutide Once Weekly in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin · 2021	This clinician	$65

Checkups this office reported

Medicare did not publish checkup rates for this clinician.

Medicare’s overall office score: 76.5 / 100; Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.

Professional record

NPI: 1659455707
Licence: CA G129600, NC 96-00991California G129600: Current · expires 2028-04-30
Trained: University of Washington School of Medicine, 1989
Group: Stanford Health Care
Video visits: Lists video visits
Gender: Male

More record details

Sole proprietor: No
Medicaid ID: NC 8953735
Taxonomy: Cardiology (207RC0000X)
Mailing address: 300 Pasteur Dr, Stanford, CA, 94305
NPI first listed: 2006-10-25
NPI last updated: 2024-04-23
NPI record certified: 2024-04-23

This is when the NPI record was last certified, not a medical board exam.